Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

PHASE2CompletedINTERVENTIONAL
Enrollment

197

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Hepatitis B Virus
Interventions
DRUG

pegIFN

Syringe, Subcutaneous, 180 μg, Once Weekly, 48 weeks

DRUG

pegIFNα-2a

Syringe, Subcutaneous 180 μg, Once Weekly, 48 Weeks

DRUG

PegIFN lambda

Syringe, Subcutaneous, 180 µg, Once weekly, 48 weeks

DRUG

Entecavir

Tablet, Oral, 0.5 mg, Once daily, 12 weeks initial monotherapy followed by 48 weeks of combination therapy with PegIFN lambda

Trial Locations (53)

100

Local Institution, Taipei

114

Local Institution, Taipei

333

Local Institution, Taoyuan District

404

Local Institution, Taichung

704

Local Institution, Tainan City

807

Local Institution, Kaohsiung City

852

Local Institution, Hong Kong

Local Institution, Tai Po

2050

Local Institution, Camperdown

2145

Local Institution, Westmead Nsw

2170

Local Institution, Liverpool

3004

Local Institution, Melbourne

3084

Local Institution, Heidelberg Vic

3168

Local Institution, Clayton Vic

6160

Local Institution, Fremantle

11355

Medical Procare, Pllc, Flushing

Office Of Sing Chan Md, Flushing

15213

University Of Pittsburgh Medical Center, Pittsburgh

20246

Local Institution, Hamburg

21045

Gastro Center Of Maryland, Colombia

21202

Mercy Medical Center, Baltimore

27710

Duke University Medical Center, Durham

30308

Atlanta Gastroenterology Associates, Llc, Atlanta

30625

Local Institution, Hanover

35033

Local Institution, Rennes

50012

Local Institution, Florence

60590

Local Institution, Frankfurt

72076

Local Institution, Tübingen

75571

Local Institution, Paris

79106

Local Institution, Freiburg im Breisgau

92105

Research And Education, Inc., San Diego

92118

Local Institution, Clichy

92801

Advanced Clinical Research Institute, Anaheim

92844

Sc Clinical Research, Inc., Garden Grove

95817

University Of California, Davis Medical Center, Sacramento

97239

Oregon Health & Science University, Portland

119228

Local Institution, Singapore

169608

Local Institution, Singapore

06520

Yale New Haven Hospital, New Haven

T2N 4Z6

Heritage Medical Research Clinic, University Of Calgary, Calgary

R3E 3P4

Local Institution, Winnipeg

M5G 2C4

Toronto General Hospital, Toronto

M5T 2S8

Toronto Western Hospital University Health Network, Toronto

06202

Local Institution, Nice

30-32

Local Institution, Shatin

00161

Local Institution, Roma

3015 CE

Local Institution, Rotterdam

200-704

Local Institution, Chuncheon

480-717

Local Institution, Gyeonggi-do

120-752

Local Institution, Seoul

135-710

Local Institution, Seoul

135-720

Local Institution, Seoul

138-736

Local Institution, Seoul

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01204762 - Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen | Biotech Hunter | Biotech Hunter